DonBensonMDPhD

Hematologic Oncology

Professor of Medicine | Myeloma Program Director | Deputy Director | Division of Hematology Vice Chair - Faculty Development| Department if Internal Medicine The Ohio State University College of Medicine The Ohio State University Comprehensive Cancer Center

Join to view full profile

Dr. Benson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Benson's full profile

Already have an account?

Office
460 W 10th Ave
Fl 5
Columbus, OH 43210
Phone+1 614-293-3196

Fax+1 614-293-6176

Summary

Care of people with myeloma | Laboratory, translational, and clinical immunotherapy research for myeloma | Medical education, teaching, and mentorship | Executive Leadership & Professional Development Coaching in medicine and health care

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Virginia Medical CenterResidency, Internal Medicine, 1999 - 2003
Northeast Ohio Medical UniversityClass of 1999

Certifications & Licensure

OH State Medical License 2003 - 2025
VA State Medical License 1999 - 2004
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Aug 01
Completed
Phase 1
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse Start of enrollment: 2010 Sep 01
Completed
Phase 1
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2011 Oct 13
Completed
Phase 2
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2012 Feb 09
Completed
Phase 1, Phase 2
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Sep 17
Completed
Phase 1
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource Start of enrollment: 2011 Mar 17
Recruiting
Roles: Contact, Principal Investigator
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

26 citations
CD94 defines phenotypically and functionally distinct mouse NK cell subsets
Jianhua Yu, Min Wei, Hsiaoyin Mao, Jianying Zhang, Tiffany Hughes
Journal of Immunology. 2009-10-15
51 citations
Leukocyte Chemotactic Factor 2 (LECT2)-Associated Renal Amyloidosis: A Case Series
Charles L. Murphy, S Wang, Daniel P. Kestler, Christopher P. Larsen, Don M. Benson
American Journal of Kidney Diseases. 2010-12-01
27 citations
RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.
Flavia Pichiorri, Sung-Suk Suh, Alberto Rocci, Luciana De Luca, Cristian Taccioli
Cancer Cell. 2010-10-19

Journal Articles

Human AML Activates the AHR Pathway to Impair NK Cell Development and Function
Luxi Chen, Michael Zhang, Monica Williams, Jennifer N Saultz, Steven D Scoville, Aharon G Freud, Don M Benson, Michael A Caligiuri, Blood

Press Mentions

Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
Colin Powell Was Fully Vaccinated, but He Still Died from COVID Complications. How Rare Is That?October 18th, 2021